#25114 TNFRSF8/CD30 (E7E4D) XP® Rabbit mAb
|内在性||90, 120||Rabbit IgG||-20℃|
|TNFRSF8/CD30 (E7E4D) XP® Rabbit mAb recognizes endogenous levels of total TNFRSF8/CD30 protein.|
|Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the extracellular domain of human TNFRSF8/CD30 protein.|
ホモロジー (相同性) 検索をご希望の場合 >>>
Western blot analysis of extracts from 293T cells, mock transfected (-) or transfected with a construct expressing Myc/DDK-tagged full-length human TNFRSF8/CD30 protein (hCD30-Myc/DDK; +), using TNFRSF8/CD30 (E7E4D) XP® Rabbit mAb (upper), DYKDDDDK Tag Antibody #2368 (middle), and β-Actin (D6A8) Rabbit mAb #8457 (lower).
Western blot analysis of extracts from various cell lines using TNFRSF8/CD30 (E7E4D) XP® Rabbit mAb (upper) and β-Actin (D6A8) Rabbit mAb #8457 (lower). As expected, TNFRSF8/CD30 protein is not expressed in either U-937 or HeLa cells. KARPAS-299 cell line source: Dr. Abraham Karpas at the University of Cambridge.
Confocal immunofluorescent analysis of HDLM-2 cells (left, high-expressing), NTERA-2 cells (middle, low-expressing) and HeLa cells (right, negative) using TNFRSF8/CD30 (E7E4D) XP® Rabbit mAb (green). Actin filaments were labeled with DyLight™ 554 Phalloidin #13054 (red). Samples were mounted in ProLong® Gold Antifade Reagent with DAPI #8961 (blue).
Flow cytometric analysis of HeLa cells (blue) and KARPAS-299 cells (green) using TNFRSF8/CD30 (E7E4D) XP® Rabbit mAb
(solid lines) or a concentration-matched Rabbit (DA1E) mAb IgG XP® Isotype Control #3900 (dashed lines). Anti-rabbit IgG (H+L), F(ab')2 Fragment (Alexa Fluor® 488 Conjugate) #4412 was used as a secondary antibody.
TNFRSF8/CD30 is a type-I transmembrane glycoprotein that is a member of the TNFR superfamily. CD30 is synthesized as a precursor protein that undergoes extensive posttranslational modification before becoming embedded in the plasma membrane as a 120-kDa transmembrane protein (1,2). The expression of CD30 is upregulated in activated T-cells and may trigger costimulatory signaling pathways upon its engagement (3,4). While its expression is normally restricted to subsets of activated T-cells and B-cells, CD30 expression is robustly upregulated in hematologic malignancies, such as Hodgkin’s lymphoma (HL), anaplastic large cell lymphoma (ALCL), and adult T-cell leukemia, thus making it an attractive target for therapeutic intervention (5,6). Research studies have suggested that in certain disease contexts, CD30 recruits TRAF2 and TRAF5 adaptor proteins to drive NF-kappa B activation, aberrant cell growth, and cytokine production (7-9). CD30 signaling is also regulated by TACE-dependent proteolytic cleavage of its ectodomain, which results in reduced CD30L-dependent activation of CD30+ cells (10, 11).
- Froese, P. et al. (1987) J Immunol 139, 2081-7.
- Nawrocki, J.F. et al. (1988) J Immunol 141, 672-80.
- Del Prete, G. et al. (1995) J Exp Med 182, 1655-61.
- Gilfillan, M.C. et al. (1998) J Immunol 160, 2180-7.
- Stein, H. et al. (1985) Blood 66, 848-58.
- Chiarle, R. et al. (1999) Clin Immunol 90, 157-64.
- Horie, R. et al. (2002) Am J Pathol 160, 1647-54.
- Horie, R. et al. (2002) Oncogene 21, 2493-503.
- Horie, R. et al. (2004) Cancer Cell 5, 353-64.
- Hansen, H.P. et al. (2000) J Immunol 165, 6703-9.
- Gruss, H.J. et al. (1997) Immunol Today 18, 156-63.
Tween is a registered trademark of ICI Americas, Inc.
XP is a registered trademark of Cell Signaling Technology, Inc.
ProLong is a registered trademark of Life Technologies Corporation.
Alexa Fluor is a registered trademark of Life Technologies Corporation.
KARPAS cell line source: Dr. Abraham Karpas at the University of Cambridge.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
DyLight is a trademark of Thermo Fisher Scientific, Inc. and its subsidiaries.